Jagsonpal Pharma

{
  "main_header": {
    "sid": 134241,
    "name": "Jagsonpal Pharma",
    "stock_name": "Jagsonpal Pharma",
    "full_name": "Jagsonpal Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/jagsonpal-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "231.00",
    "chg": 8.6,
    "chgp": "3.87%",
    "dir": 1,
    "prev_price": "222.40",
    "mcapval": "1,488.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 507789,
    "symbol": "JAGSNPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE048B01035",
    "curr_date": "Jun 23, 03:30 PM",
    "curr_time": "05:21 AM",
    "last_traded_at": "Jun 23, 03:30 PM IST",
    "bse_nse_vol": "4.74 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 23, 2026",
    "traded_date_str": "2026 06 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jagsonpal-pharma-134241-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Jagsonpal Pharmaceuticals Gains 0.74%: 5 Key Factors Driving the Week's Mixed Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-gains-074-5-key-factors-driving-the-weeks-mixed-momentum-4066348",
        "imagepath": "",
        "date": "2026-06-21 16:00:54",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>15 Jun:</strong> Golden Cross formation signals potential bullish breakout</p>\n                    <p><strong>15 Jun:</strong> Upgrade from Strong Sell to Sell on technical improvements</p>\n                    <p><strong>17 Jun:</strong> Technical momentum shifts to bullish despite price dip</p>\n                    <p><strong>18 Jun:</strong> Upgrade from Sell to Hold amid improving technicals</p>\n                    <p><strong>19 Jun:</strong> Stock closes at Rs.212.35, up 1.00% on high volume</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.210.80</div>..."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Upgraded to Hold on Technical Improvement Despite Financial Setbacks",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-upgraded-to-hold-on-technical-improvement-despite-financial-setbacks-4060551",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_mojoScore_4060551.png",
        "date": "2026-06-18 08:10:26",
        "description": "Jagsonpal Pharmaceuticals Ltd has seen its investment rating upgraded from Sell to Hold as of 17 June 2026, driven primarily by a marked improvement in technical indicators despite recent negative financial results. The company’s micro-cap status and mixed fundamental signals have led to a cautious stance, with the upgrade reflecting a nuanced balance between valuation, quality, financial trends, and technical momentum."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-market-signals-4057949",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_technicaldot_4057949.png",
        "date": "2026-06-17 08:00:19",
        "description": "Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend on the weekly charts. Despite a recent day decline of 1.95%, the stock’s technical indicators reveal a complex interplay of signals that investors should carefully analyse before making decisions."
      },
      {
        "title": "Golden Cross Confirmed: Do Jagsonpal Pharmaceuticals Ltd's Other Technical Indicators Agree?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-ltd-forms-golden-cross-signalling-potential-bullish-breakout-4054638",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_goldencross_4054638.png",
        "date": "2026-06-15 18:00:13",
        "description": "The 50-day moving average has crossed above the 200-day moving average for Jagsonpal Pharmaceuticals Ltd, signalling a golden cross on 15 Jun 2026. Yet, the broader technical and fundamental context presents a nuanced picture that calls for a closer look at the reliability of this signal."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Upgraded to Sell on Technical Improvements Despite Financial Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-upgraded-to-sell-on-technical-improvements-despite-financial-challenges-4053545",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_mojoScore_4053545.png",
        "date": "2026-06-15 08:04:18",
        "description": "Jagsonpal Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 12 June 2026, driven primarily by a shift in technical indicators despite ongoing financial headwinds. The company’s Mojo Score rose to 42.0, reflecting a more positive technical outlook, although fundamental concerns remain. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd Shows Mixed Technical Signals Amid Mildly Bullish Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-ltd-shows-mixed-technical-signals-amid-mildly-bullish-momentum-4053306",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_technicaldot_4053306.png",
        "date": "2026-06-15 08:00:13",
        "description": "Jagsonpal Pharmaceuticals Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish trend on weekly charts, despite mixed signals across monthly indicators. The micro-cap pharmaceutical company’s recent price action and technical parameters suggest cautious optimism for investors, even as the MarketsMOJO rating remains a Sell with a recent upgrade from Strong Sell."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-ltd-is-rated-strong-sell-4036722",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_mojoScore_4036722.png",
        "date": "2026-06-06 10:10:48",
        "description": "Jagsonpal Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Declines 1.39% Amid Strong Sell Downgrade and Mixed Technical Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-declines-139-amid-strong-sell-downgrade-and-mixed-technical-signals-4024698",
        "imagepath": "",
        "date": "2026-05-31 16:01:28",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>25 May:</strong> Stock opens at Rs.209.30, closes lower at Rs.205.20 (-1.96%) amid downgrade news</p>\n                    <p><strong>26 May:</strong> Downgrade to Strong Sell announced; technical indicators shift to mildly bearish</p>\n                    <p><strong>27 May:</strong> Stock recovers slightly to Rs.209.20 (+0.92%) on moderate volume</p>\n                    <p><strong>29 May:</strong> Week closes at Rs.206.40 (-1.34%), underperforming Sensex</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.209.30</div></div>\n                    <div class=\"sta..."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Downgraded to Strong Sell Amid Technical and Financial Weakness",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-downgraded-to-strong-sell-amid-technical-and-financial-weakness-4012889",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JagsonpalPharma_mojoScore_4012889.png",
        "date": "2026-05-26 08:18:17",
        "description": "Jagsonpal Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its technical indicators, valuation metrics, financial trends, and overall quality. The downgrade reflects growing concerns over the company’s recent quarterly performance, deteriorating technical signals, and expensive valuation relative to its peers, despite its net-debt-free status."
      }
    ],
    "total": 268,
    "sid": "134241",
    "stock_news_url": "https://www.marketsmojo.com/news/jagsonpal-pharmaceuticals-134241"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
      "datetime": "04-Jun-2026",
      "details": "Allotment of 296320 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Closure of Buy Back",
      "datetime": "02-Jun-2026",
      "details": "Extinguishment of 1600000 Equity Shares of Jagsonpal Pharmaceuticals Limited.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "28-May-2026",
      "details": "Please find enclosed Annual Secretarial Compliance Report for the Financial Year ended March 31 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has declared <strong>125%</strong> dividend, ex-date: 12 Sep 25",
          "dt": "2025-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has announced <strong>2:5</strong> stock split, ex-date: 08 Jan 25",
          "dt": "2025-01-08",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Jagsonpal Pharmaceuticals Gains 0.74%: 5 Key Factors Driving the Week's Mixed Momentum

2026-06-21 16:00:54

Key Events This Week

15 Jun: Golden Cross formation signals potential bullish breakout

15 Jun: Upgrade from Strong Sell to Sell on technical improvements

17 Jun: Technical momentum shifts to bullish despite price dip

18 Jun: Upgrade from Sell to Hold amid improving technicals

19 Jun: Stock closes at Rs.212.35, up 1.00% on high volume

Week Open

Rs.210.80

...

Read full news article

Jagsonpal Pharmaceuticals Upgraded to Hold on Technical Improvement Despite Financial Setbacks

2026-06-18 08:10:26

Jagsonpal Pharmaceuticals Ltd has seen its investment rating upgraded from Sell to Hold as of 17 June 2026, driven primarily by a marked improvement in technical indicators despite recent negative financial results. The company’s micro-cap status and mixed fundamental signals have led to a cautious stance, with the upgrade reflecting a nuanced balance between valuation, quality, financial trends, and technical momentum.

Read full news article

Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-06-17 08:00:19

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend on the weekly charts. Despite a recent day decline of 1.95%, the stock’s technical indicators reveal a complex interplay of signals that investors should carefully analyse before making decisions.

Read full news article

Golden Cross Confirmed: Do Jagsonpal Pharmaceuticals Ltd's Other Technical Indicators Agree?

2026-06-15 18:00:13

The 50-day moving average has crossed above the 200-day moving average for Jagsonpal Pharmaceuticals Ltd, signalling a golden cross on 15 Jun 2026. Yet, the broader technical and fundamental context presents a nuanced picture that calls for a closer look at the reliability of this signal.

Read full news article

Jagsonpal Pharmaceuticals Upgraded to Sell on Technical Improvements Despite Financial Challenges

2026-06-15 08:04:18

Jagsonpal Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 12 June 2026, driven primarily by a shift in technical indicators despite ongoing financial headwinds. The company’s Mojo Score rose to 42.0, reflecting a more positive technical outlook, although fundamental concerns remain. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change.

Read full news article

Jagsonpal Pharmaceuticals Ltd Shows Mixed Technical Signals Amid Mildly Bullish Momentum

2026-06-15 08:00:13

Jagsonpal Pharmaceuticals Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish trend on weekly charts, despite mixed signals across monthly indicators. The micro-cap pharmaceutical company’s recent price action and technical parameters suggest cautious optimism for investors, even as the MarketsMOJO rating remains a Sell with a recent upgrade from Strong Sell.

Read full news article

Jagsonpal Pharmaceuticals Ltd is Rated Strong Sell

2026-06-06 10:10:48

Jagsonpal Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Jagsonpal Pharmaceuticals Declines 1.39% Amid Strong Sell Downgrade and Mixed Technical Signals

2026-05-31 16:01:28

Key Events This Week

25 May: Stock opens at Rs.209.30, closes lower at Rs.205.20 (-1.96%) amid downgrade news

26 May: Downgrade to Strong Sell announced; technical indicators shift to mildly bearish

27 May: Stock recovers slightly to Rs.209.20 (+0.92%) on moderate volume

29 May: Week closes at Rs.206.40 (-1.34%), underperforming Sensex

Week Open

Rs.209.30

Read full news article

Jagsonpal Pharmaceuticals Downgraded to Strong Sell Amid Technical and Financial Weakness

2026-05-26 08:18:17

Jagsonpal Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its technical indicators, valuation metrics, financial trends, and overall quality. The downgrade reflects growing concerns over the company’s recent quarterly performance, deteriorating technical signals, and expensive valuation relative to its peers, despite its net-debt-free status.

Read full news article

View All News